| Literature DB >> 25414775 |
Hoyoung Lee1, Hyekyung Ha2, Jun Kyoung Lee2, Sang-Joon Park3, Seung-Ii Jeong4, Hyeun Kyoo Shin2.
Abstract
Broussonetia kazinoki Siebold. (B. kazinoki) has long been used in the manufacture of paper in Asian countries. Although B. kazinoki leaves (BK) have been employed in dermatological therapy, use of BK has not been tested in patients with atopic dermatitis (AD). Using Nc/Nga mice, which are genetically predisposed to develop AD-like skin lesions, we confirmed the efficacy of BK in AD treatment. BK extract was applied topically to Dermatophagoides farinae-induced AD-like lesions in Nc/Nga mice, and the effects were assessed both clinically and by measuring skin thickness on the back and ears. We measured the effects of BK extract on plasma levels of IgE and IL-4. We also measured the ability of BK extract to inhibit the secretion of hTARC in HaCaT cells after stimulation by TNF-α and IFN-γ. We found that BK extract significantly reduced ear and dorsal skin thickness and the clinical signs of AD, as well as significantly down-regulating the plasma levels of IgE and IL-4 (p<0.01 for each comparison). Moreover, 500 μg/mL of BK extract inhibited hTARC secretion in HaCaT cells by activated TNF-α/IFN-γ by about 87%. These findings suggest that topical application of BK extract has excellent potential in the treatment of AD.Entities:
Keywords: Atopic dermatitis; Broussonetia kazinoki Siebold.; Dermatophagoides farina; TARC
Year: 2014 PMID: 25414775 PMCID: PMC4201232 DOI: 10.4062/biomolther.2014.023
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Phytochemical analysis of Broussonetia kazinoki Siebold leaves (BK) extract
| Constituent | mg/g BK extract |
|---|---|
| Flavonoids | 24 ± 0.7 |
| Tannins | 14 ± 0.6 |
| Total phenolics | 22 ± 0.3 |
The data are presented as mean ± SEM (n=3).
Fig. 1.Clinical and histological features on atopic dermatities-like skin lesions topically treated with Broussonetia kazinoki Sieb leaves. (A) The group of untreated (cont), D. farinae plus vehicle-treated (D. farinae), D. farinae plus tacrolimus (Protopic®) treated (Protopic) and D. farinae plus Broussonetia kazinoki Sieb leaves (BK) treated Nc/Nga mice were excised (B) Clinical feature of ear and skin. (C) The dermatitis score on atopic dermatitis-like skin lesions (##p<0.01 compare with 0 week, *p<0.05 compare with D. farinae, **p<0.01).
Fig. 2.Infilteration of mast cells into the skin on atopic dermatitis-induced Nc/Nga mice. The group of untreated (cont), D. farinae plus vehicle-untreated (D. farinae), D. farinae plus tacrolimus-treated (Protopic) and D. farinae plus Broussonetia kazinoki Sieb leaves (BK) treated Nc/Nga mice were excised (A) The dorsal skin sections were stained with toludine blue. (B) The number of mast cells was counted (**p<0.01 compare with D. farinae.).
Fig. 3.Plasma levels of IL-4 and IgE in atopic dermatitis-induced Nc/Nga mice. The plasma samples were collected from untreated (Cont), D. farinae plus vehicle-treated (D. farinae), D. farinae plus tacrolimus-treated (Protopic) and D. farinae plus Broussonetia kazinoki Sieb leaves (BK) treated Nc/Nga mice. The plasma concentrations of IgE (A) and IL-4 (B) were measured by ELISA (*p<0.05 compare with D. farinae, **p<0.01).
Fig. 4.The hTARC production on TNF-α/IFN-γ stimulated Ha-CatT cells. The HaCaT cells were incubated in medium containing Broussonetia kazinoki Sieb leaves (BK) and treated with TNF-α/IFN-γ (TI) (10 ng/mL, each) for 24 hr. The concentration of hTARC in the medium was determined using ELISA (*p<0.05 compare with TI group, **p<0.01).